A Study Comparing Degu Insulin Liraglutide Injection With Premixed Insulin on the Prognosis of Diabetes Mellitus

Launched by BEIJING TSINGHUA CHANG GUNG HOSPITAL · Apr 11, 2025

Keywords

ClinConnect Summary

This study is testing whether switching adults with type 2 diabetes from their current premixed insulin to a new treatment called Degludec insulin liraglutide injection helps people reach and keep their blood sugar in a healthy range faster than continuing their usual insulin plan. It’s a randomized, open-label trial (people and doctors know which treatment is being used) with about 170 participants. The main goal is to see how long it takes to get morning fasting glucose to a target and keep overall blood sugar in a safe range (measured with a continuous glucose monitor), after a short initial dose-adjustment period.

Who can join: adults aged 18–75 with type 2 diabetes for more than 6 months, who have been using premixed insulin or similar therapy for at least 3 months and have a screening HbA1c between 7.0% and 8.0%. Participants should be able to monitor their blood sugar at home and have a BMI between 18 and 35. There are several safety rules to exclude people with certain health conditions or recent serious illnesses, allergies to insulin, recent use of GLP-1 drugs, pregnancy, or other factors that could affect the study results. If eligible, you’ll go through a 14-day dose-adjustment period to aim for fasting morning glucose under 7.5 mmol/L, then about 14 days of glucose monitoring with CGM, plus blood tests for a marker called glycated albumin and stool tests to study gut bacteria. The new therapy starts at about 80% of your current daily insulin dose, with adjustments as needed.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Voluntarily sign the informed consent form;
• • 2. Male and female between the ages of 18 and 75 (inclusive);
• • 3. Diagnosed with type 2 diabetes mellitus according to WHO standards (1999) for more than 6 months;
• • 4. Those who use premixed human insulin or insulin analogues with or without oral hypoglycemic drugs (which cannot contain secretagogues and DPP4 inhibitors) \>=3 months, and have poor blood sugar control;
• • 5. Glycosylated hemoglobin \> 7.0% and \<=8.0% at screening;
• • 6. Body mass index (BMI) \> 18 kg/m\^2 and \<=35 kg/m\^2;
• • 7. Those who are willing and able to use the blood glucose meter for self-blood glucose monitoring according to the requirements of the program.
• Exclusion Criteria:
• • 1. People who are known to be allergic to Degu insulin or ingredients in its preparations;
• • 2. Human glucagon-like peptide-1 (GLP-1) receptor agonist has been used within 3 months before screening;
• • 3. Patients with hypoglycemic coma within 3 months before screening;
• • 4. Patients with severe ketosis or ketoacidosis within 1 month before screening;
• • 5. Severe complications of diabetes at the time of screening: such as severe proliferative diabetic retinopathy, a history of kidney transplantation, active peripheral vascular disease (such as diseases that have led to amputation, chronic foot ulcers, intermittent claudication, or require interventional procedures such as bypass or angioplasty);
• • 6. Severe hypertension that cannot be controlled by treatment (defined as systolic blood pressure of not less than 180mmHg and/or diastolic blood pressure of not less than 100mmHg);
• • 7. Patients with acute myocardial infarction, uncontrolled angina pectoris, uncontrolled arrhythmia, or severe heart failure (NYHA grading ≥III) in the 12 months prior to screening; New cerebrovascular accidents (including ischemic stroke, hemorrhagic stroke and transient ischemic attack) within 6 months prior to screening;
• • 8. Liver and kidney function impairment: ALT, AST greater than 2.5 times the upper limit of normal, serum creatinine greater than 1.5 times the upper limit of normal;
• • 9. Any conditions or co-existing diseases that the investigator determines may interfere with the test results, such as cardiovascular, respiratory, gastrointestinal, pancreatic, liver, kidney, nervous system, psychiatric, hematological (such as hematological tumors, hemolytic anemia, sickle cell disease, etc.), immune system, or other malignant tumors;
• • 10. Mental disorder, unwilling to communicate or language barriers, unable to fully understand, cooperate and use the blood glucose meter;
• • 11. Drugs that may have a significant effect on glucose metabolism, such as systemic corticosteroids, monoamine oxidase inhibitors, etc. are expected to be used within 3 months prior to screening;
• • 12. Participated in other drug or device clinical studies 3 months before participating in this study;
• • 13. Have a history of drug abuse and alcohol dependence in the past 5 years;
• • 14. Known pregnancies (determined by pregnancy tests at the time of screening), women who are preparing to become pregnant or are lactating at the time of the test, or women of childbearing age who are unable to take adequate contraception (adequate contraception means Iuds, oral contraceptives and barrier measures);
• • 15. Patients deemed unsuitable for participation in this study by the investigator;
• • 16. Antibiotics and probiotics were used within 3 months before screening;
• • 17. Family history of medullary thyroid cancer or medullary thyroid cancer or family history of MEN.